These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8826903)

  • 1. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups.
    Menache D; Aronson DL; Darr F; Montgomery RR; Gill JC; Kessler CM; Lusher JM; Phatak PD; Shapiro AD; Thompson AR; White GC
    Br J Haematol; 1996 Sep; 94(4):740-5. PubMed ID: 8826903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2.
    Menache D
    Haemophilia; 1998; 4 Suppl 3():44-7. PubMed ID: 10028318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
    Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
    Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
    Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
    J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
    Lethagen S; Berntorp E; Nilsson IM
    Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
    Mannucci PM; Lombardi R; Castaman G; Dent JA; Lattuada A; Rodeghiero F; Zimmerman TS
    Blood; 1988 Jan; 71(1):65-70. PubMed ID: 3257148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
    Vukovich TC
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.
    Goudemand J; Scharrer I; Berntorp E; Lee CA; Borel-Derlon A; Stieltjes N; Caron C; Scherrmann JM; Bridey F; Tellier Z; Federici AB; Mannucci PM
    J Thromb Haemost; 2005 Oct; 3(10):2219-27. PubMed ID: 16194199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease--results based on an epidemiological investigation.
    Rodeghiero F; Castaman G; Tosetto A
    Thromb Haemost; 1990 Nov; 64(3):349-52. PubMed ID: 2096485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.